Press release
Onychomycosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Clinical Trials By DelveInsight | Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Moberg Pharma, Sato Pharma
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Onychomycosis pipeline constitutes 11+ key companies continuously working towards developing 11+ Onychomycosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Onychomycosis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Onychomycosis Market.
The Onychomycosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Onychomycosis Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Onychomycosis treatment therapies with a considerable amount of success over the years.
*
Onychomycosis companies working in the treatment market are Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, MediQuest Therapeutics, Polichem S.A, Repolar Ltd., Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A., Pfizer, Bausch Health, Halcygen Pharma, Meiji Seika Pharma, photonamic GmbH, Viamet, Novartis, Topica Pharma, Taro Pharma, NanoBio Crp, Hallux, Inc., Merck Sharp & Dohme, Bayer, Abeona Therapeutics, Dow Pharma, Taro Pharma, and others, are developing therapies for the Onychomycosis treatment
*
Emerging Onychomycosis therapies in the different phases of clinical trials are- MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Organogel of naftifine, Amorolfine, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, AN2690, Efinaconazole, SUBA-itraconazole, ME1111, PD P 506 A, VT-1161, terbinafine, Luliconazole, NVXT topical, NB-002, HTS-519, SCH 56592, Bifonazole cream 1%, EcoNail Trademark , IDP-108, Itraconazole, and others are expected to have a significant impact on the Onychomycosis market in the coming years.
*
Acquired by Pfizer, Anacor Pharmaceuticals Inc. has made notable advancements in the treatment of dermatophytic onychomycosis. Their topical antifungal product, Kerydin (tavaborole), is well-regarded for its effectiveness in treating onychomycosis.
*
Johnson & Johnson, via its subsidiary Janssen Pharmaceuticals, plays a significant role in the dermatophytic onychomycosis treatment market. The company's focus on research and development has resulted in the development of effective antifungal treatments. Johnson & Johnson's extensive distribution network and strong brand reputation ensure their treatments are widely accessible.
Onychomycosis Overview
Onychomycosis is a fungal infection that affects the nails, typically the toenails but sometimes the fingernails as well. This condition, also known as tinea unguium, is caused by various types of fungi, including dermatophytes, yeasts, and non-dermatophyte molds.
Get a Free Sample PDF Report to know more about Onychomycosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/onychomycosis-pipeline-insight [https://www.delveinsight.com/report-store/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Onychomycosis Drugs Under Different Phases of Clinical Development Include:
*
MOB-015: Moberg Pharma
*
BB2603: Blueberry Therapeutics
*
HSG: Hallux
*
Tavaborole: Pfizer
*
MOB015B: Moberg Pharma AB
*
P-3058: Polichem S.A.
*
Organogel of naftifine: MediQuest Therapeutics
*
Amorolfine: Repolar Ltd.
*
TDT067 and Lamisil: Celtic Pharma
*
Albaconazole: GlaxoSmithKline
*
HTU-520: Hisamitsu Pharma
*
P-3058: Polichem S.A.
*
AN2690: Pfizer
*
Efinaconazole: Bausch Health
*
SUBA-itraconazole: Halcygen Pharma
*
ME1111: Meiji Seika Pharma
*
PD P 506 A: photonamic GmbH
*
VT-1161: Viamet
*
terbinafine: Novartis
*
Luliconazole: Topica Pharma
*
NVXT topical: Taro Pharma
*
NB-002: NanoBio Crp
*
HTS-519: Hallux, Inc.
*
SCH 56592: Merck Sharp & Dohme
*
Bifonazole cream 1%: Bayer
*
EcoNail Trademark : Abeona Therapeutics
*
IDP-108: Dow Pharma
*
Itraconazole: Taro Pharma
Onychomycosis Route of Administration
Onychomycosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Onychomycosis Molecule Type
Onychomycosis Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Onychomycosis Pipeline Therapeutics Assessment
*
Onychomycosis Assessment by Product Type
*
Onychomycosis By Stage and Product Type
*
Onychomycosis Assessment by Route of Administration
*
Onychomycosis By Stage and Route of Administration
*
Onychomycosis Assessment by Molecule Type
*
Onychomycosis by Stage and Molecule Type
DelveInsight's Onychomycosis Report covers around 11+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Onychomycosis product details are provided in the report. Download the Onychomycosis pipeline report to learn more about the emerging Onychomycosis therapies [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Onychomycosis Therapeutics Market include:
Key companies developing therapies for Onychomycosis are - Bausch Health Companies, Celtic Pharma, Galderma S.A., Johnson & Johnson, Anacor Pharmaceuticals Inc., Pfizer Inc., GlaxoSmithKline Plc, Novartis AG, Topica Pharmaceuticals Inc., Bayer AG, Moberg Pharma AB, Allergen Inc., Cipla Ltd, Reddy's Laboratories Ltd, Sanofi S.A., Merz Pharma, Medimetriks Pharmaceuticals Inc., NovaBiotics Inc., ZimVie Inc., Wieland Dental, Teva Pharmaceutical Industries Ltd., Cardinal Health Inc., Zimmer Biomet, ZimVie Inc., Lumenis Ltd, Blueberry Therapeutics, Viatris Inc., Cardinal Health Inc., Valeant Pharmaceuticals International Inc., IMARC Group, Almirall S.A., and others.
Onychomycosis Pipeline Analysis:
The Onychomycosis pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Onychomycosis with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Onychomycosis Treatment.
*
Onychomycosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Onychomycosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Onychomycosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Onychomycosis drugs and therapies [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Onychomycosis Pipeline Strengths
*
The introduction of novel, inexpensive, and non-invasive diagnostic technologies have led to rapid and accurate diagnosis of onychomycosis, hence increasing the rate of diagnosis.
Onychomycosis Pipeline Market Opportunities
*
Current treatments have poor adherence and tolerability creating an opportunity for the key players to work on these areas
Scope of Onychomycosis Pipeline Drug Insight
*
Coverage: Global
*
Key Onychomycosis Companies: Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, MediQuest Therapeutics, Polichem S.A, Repolar Ltd., Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A., Pfizer, Bausch Health, Halcygen Pharma, Meiji Seika Pharma, photonamic GmbH, Viamet, Novartis, Topica Pharma, Taro Pharma, NanoBio Crp, Hallux, Inc., Merck Sharp & Dohme, Bayer, Abeona Therapeutics, Dow Pharma, Taro Pharma, and others
*
Key Onychomycosis Therapies: MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Organogel of naftifine, Amorolfine, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, AN2690, Efinaconazole, SUBA-itraconazole, ME1111, PD P 506 A, VT-1161, terbinafine, Luliconazole, NVXT topical, NB-002, HTS-519, SCH 56592, Bifonazole cream 1%, EcoNail Trademark , IDP-108, Itraconazole, and others
*
Onychomycosis Therapeutic Assessment: Onychomycosis current marketed and Onychomycosis emerging therapies
*
Onychomycosis Market Dynamics: Onychomycosis market drivers and Onychomycosis market barriers
Request for Sample PDF Report for Onychomycosis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Onychomycosis Report Introduction
2. Onychomycosis Executive Summary
3. Onychomycosis Overview
4. Onychomycosis- Analytical Perspective In-depth Commercial Assessment
5. Onychomycosis Pipeline Therapeutics
6. Onychomycosis Late Stage Products (Phase II/III)
7. Onychomycosis Mid Stage Products (Phase II)
8. Onychomycosis Early Stage Products (Phase I)
9. Onychomycosis Preclinical Stage Products
10. Onychomycosis Therapeutics Assessment
11. Onychomycosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Onychomycosis Key Companies
14. Onychomycosis Key Products
15. Onychomycosis Unmet Needs
16 . Onychomycosis Market Drivers and Barriers
17. Onychomycosis Future Perspectives and Conclusion
18. Onychomycosis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=onychomycosis-pipeline-trends-2024-clinical-trials-therapeutic-innovations-and-clinical-trials-by-delveinsight-blueberry-therapeutics-hallux-pfizer-bausch-health-moberg-pharma-sato-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Onychomycosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Clinical Trials By DelveInsight | Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Moberg Pharma, Sato Pharma here
News-ID: 3574992 • Views: …
More Releases from ABNewswire

Bridging Telecom and Cloud: A H M Jafor's Leadership in Transforming Global Comm …
Image: https://www.abnewswire.com/upload/2025/08/3d9231bfcc0c6ae5ee9c39393be99089.jpg
In the ever-evolving landscape of global telecommunications, few professionals stand out for their visionary leadership and commitment to innovation like A H M Jafor [https://scholar.google.com/citations?user=ZvcNANQAAAAJ&hl=en]. As Senior Manager of International Carrier Relations at NovoTel Ltd, Bangladesh, Jafor has been a pivotal figure in transforming how telecom and cloud technologies intersect, thereby shaping the future of global communication. With over a decade of hands-on experience in both the telecom and…

CRM + Booking Integration: How Bitrix24 Is Revolutionizing Business Operations i …
Image: https://www.abnewswire.com/upload/2025/08/3b1b46307a609effec9c81b325e7a4d9.jpg
In today's hyper-competitive business landscape, the integration of Customer Relationship Management (CRM) systems with booking platforms has become more than just a convenience - it's a strategic necessity that's transforming how successful companies operate.
Leading this revolution is Bitrix24, whose innovative CRM with Booking solution [https://www.bitrix24.com/tools/websites/landing-pages.php] has helped over 15 million organizations worldwide streamline their operations and boost revenue by up to 30%. As we navigate through 2025, businesses that…

VidMate Redefines Digital Entertainment with Seamless Video and Music Downloads
Image: https://www.abnewswire.com/upload/2025/08/36d7b33dce79622e8d8df37fff6f9e2f.jpg
Introduction
In today's digital world, streaming videos, music, and images has become a daily routine for millions of people. However, many users often struggle with unreliable internet connections, limited storage options, or restrictions from platforms that do not allow direct downloads. This is where VidMate, a free Android application, becomes the perfect solution.
VidMate enables users to download videos, music, and pictures in high quality from almost any platform, including YT,…

Vograce Introduces High-Quality Custom Acrylic Keychains for Creative Branding S …
Image: https://www.abnewswire.com/upload/2025/08/96fd20a79da68a1056770c7a31d077f7.jpg
Introduction: Why Custom Acrylic Keychains Are a Smart Choice
At one time or another, you may have considered practices that can give your brand, event or beats a boost but custom acrylic keychains are one of the most cost effective yet dynamic options you can utilize. They are tiny, convenient and attractive. Nonetheless, not every keychain is good. Poor quality printing, substandard paper, or lifeless colors will make their appearance…
More Releases for Onychomycosis
Rising Diabetic Population Fuels Onychomycosis Market Growth: Powering Innovatio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Onychomycosis Market Through 2025?
In recent times, the onychomycosis market has experienced robust growth. It is projected to expand from $3.63 billion in 2024 to $3.83 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.4%. The growth seen in…
Rising Diabetic Population Fuels Onychomycosis Market Growth: A Significant Driv …
The Onychomycosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Onychomycosis Market Size and Projected Growth Rate?
The market for onychomycosis has seen substantial growth in recent times. The market size is predicted to rise from $3.63 billion in 2024 to $3.83 billion…
Onychomycosis Market Insights and Development Trends
The Onychomycosis Market Is Set To Grow At An Estimated CAGR Of 8.5% From 2025 To 2034, Rising From $7.8 Billion In 2024 To $14.5 Billion By 2034.
On March 21, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Onychomycosis market goods. The market study excludes key regions that are accelerating marketization. This section also gives…
Onychomycosis Treatment Market Size & Share Analysis
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Onychomycosis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $4.73 billion In 2028 At…
Onychomycosis Therapeutics Market - Empowering Nail Wellness, Inspiring Beautifu …
Newark, New Castle, USA - new report, titled Onychomycosis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Onychomycosis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Onychomycosis Therapeutics market. The report offers an overview of the market, which…
Dermatophytic Onychomycosis Therapeutics (DOT) Market
Market growth is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Easy application of nail paints is also expected to drive demand for dermatophytic onychomycosis drugs. However, adverse effects associated with anti-fungal drugs and lack of awareness about dermatophytic onychomycosis in Asia Pacific, Middle East and Africa, and Latin…